XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$148.05-0.48%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
54/100
Moderate
Score components
TickerWhale View
Merck & Co scores 54 out of 100 overall, which we rate moderate. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Risk
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
Quality & growth
30%36Weak
- Revenue growth 4.6%
- EPS growth -80.7%
Valuation
25%39Weak
- P/E 115.2
- EV/Sales 6.2
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
#29 by market cap in our coverage · ~75,000 employees · Listed 1949-04-20 · www.merck.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#79 / 139sector rank by TickerWhale Score
TickerWhale Score 54 vs sector average 54.6 (-0.6)
Revenue growth (industry)Top 64%
Gross margin (industry)Top 55%
Return on equity (industry)Top 70%
P/E (industry)Pricier than 90%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
86/100Strong vs universe
Ranks 86th of 100 covered names on our technical composite — the composite itself scores 78/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
5 buy · 0 sell · 3 neutral of 8 votes
TickerWhale rates MRK's technical setup strong — 86th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+15.6%
- vs 50-day+1.1%
Momentum
Mixed
- RSI (14)53 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength21· trending
- MACD (12,26,9)buy(histogram 0.297)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 0 sell · 3 neutral.
Result — 5 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)115.2
- P/S (TTM)5.5
- P/B8.7
- EV/EBITDA—
- EV/Sales6.2
- PEG—
Profitability & returns
- Gross margin73.0%
- Net margin4.8%
- ROE7.2%
- Debt/Equity1.29
Growth
- Revenue growth (YoY)4.6%
- EPS growth (YoY)-80.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $365.7B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $65.0B | $64.2B | $60.1B |
| Gross profit | $48.6B | $49.0B | $44.0B |
| Operating income | $21.2B | $19.9B | $2.4B |
| Net income | $18.3B | $17.1B | $365M |
| EPS (diluted) | $7.28 | $6.74 | $0.14 |
| Free cash flow | $12.4B | $18.1B | $9.1B |
| Cash | $14.6B | $13.2B | $6.8B |
| Total debt | $49.3B | $37.1B | $35.1B |
| Equity | $52.6B | $46.3B | $37.6B |
| Net debt | $34.8B | $23.9B | $28.2B |
| Debt / equity | 0.94 | 0.80 | 0.93 |
| Liabilities / assets | 0.62 | 0.60 | 0.65 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRKCurrentMerck & Co | 54 | 78 | 115.2 | — | 8.7 | 6.2 | $148.05 | -0.48% | +4.6% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.